| Literature DB >> 34544282 |
Vincent Morcilla1, Charline Bacchus-Souffan2, Katie Fisher1,3, Bethany A Horsburgh1,3, Bonnie Hiener1,3, Xiao Qian Wang1,3, Timothy E Schlub4, Mark Fitch5, Rebecca Hoh6, Frederick M Hecht6, Jeffrey N Martin6, Steven G Deeks6, Marc K Hellerstein5, Joseph M McCune7, Peter W Hunt2, Sarah Palmer1,3.
Abstract
Future HIV-1 curative therapies require a thorough understanding of the distribution of genetically-intact HIV-1 within T-cell subsets during antiretroviral therapy (ART) and the cellular mechanisms that maintain this reservoir. Therefore, we sequenced near-full-length HIV-1 genomes and identified genetically-intact and genetically-defective genomes from resting naive, stem-cell memory, central memory, transitional memory, effector memory, and terminally-differentiated CD4+ T-cells with known cellular half-lives from 11 participants on ART. We find that a higher infection frequency with any HIV-1 genome was significantly associated with a shorter cellular half-life, such as transitional and effector memory cells. A similar enrichment of genetically-intact provirus was observed in these cells with relatively shorter half-lives. We found that effector memory and terminally-differentiated cells also had significantly higher levels of expansions of genetically-identical sequences, while only transitional and effector memory cells contained genetically-intact proviruses that were part of a cluster of identical sequences. Expansions of identical sequences were used to infer cellular proliferation from clonal expansion. Altogether, this indicates that specific cellular mechanisms such as short half-life and proliferative potential contribute to the persistence of genetically-intact HIV-1. IMPORTANCE The design of future HIV-1 curative therapies requires a more thorough understanding of the distribution of genetically-intact HIV-1 within T-cell subsets as well as the cellular mechanisms that maintain this reservoir. These genetically-intact and presumably replication-competent proviruses make up the latent HIV-1 reservoir. Our investigations into the possible cellular mechanisms maintaining the HIV-1 reservoir in different T-cell subsets have revealed a link between the half-lives of T-cells and the level of proviruses they contain. Taken together, we believe our study shows that more differentiated and proliferative cells, such as transitional and effector memory T-cells, contain the highest levels of genetically-intact proviruses, and the rapid turnover rate of these cells contributes to the expansion of genetically-intact proviruses within them. Therefore, our study delivers an in-depth assessment of the cellular mechanisms, such as cellular proliferation and half-life, that contribute to and maintain the latent HIV-1 reservoir.Entities:
Keywords: cell proliferation; cellular half-life; human immunodeficiency virus; persistence
Mesh:
Year: 2021 PMID: 34544282 PMCID: PMC8546577 DOI: 10.1128/mBio.02447-21
Source DB: PubMed Journal: mBio Impact factor: 7.867
Participant demographics
| Group and SCOPE PID | Sex | Age | Viral load | CD4+ T-cell count | Time of infection before initiation of therapy (mo) | ART duration | ART duration |
|---|---|---|---|---|---|---|---|
| Early | |||||||
| 2647 | Male | 33 | <40 | 532 | 4.5 | 3.4 | Short |
| 2531 | Male | 51 | <40 | 1,163 | 1.9 | 3.4 | Short |
| 2664 | Male | 46 | <40 | 637 | 4.1 | 2.7 | Short |
| 2606 | Male | 29 | <40 | 787 | 1.7 | 3.5 | Short |
| 2454 | Male | 35 | <40 | 513 | 0.7 | 7.1 | Long |
| 2661 | Male | 54 | <40 | 739 | 3.4 | 12.9 | Long |
| Late | |||||||
| 1408 | Male | 31 | <40 | 637 | 45.5 | 3.1 | Short |
| 3632 | Male | 31 | <40 | 902 | 20.8 | 1.8 | Short |
| 1756 | Male | 29 | <40 | 582 | 6.8 | 4.1 | Short |
| 2274 | Male | 54 | <40 | 486 | 13.1 | 11.8 | Long |
| 2208 | Male | 64 | <40 | 437 | 114.5 | 7.1 | Long |
At the time of sampling.
Cellular half-lives for each subset and participant
| Group and SCOPE PID | Half-life (days) | |||||
|---|---|---|---|---|---|---|
| NV | SCM | CM | TM | EM | TD | |
| Early | ||||||
| 2647 | 488 | 160 | 103 | 94 | 88 | 165 |
| 2531 | 839 | 258 | 149 | 111 | 82 | 274 |
| 2664 | 2,484 | 184 | 202 | 143 | 151 | 536 |
| 2606 | 1,451 | 138 | 145 | 114 | 156 | 296 |
| 2454 | 2,146 | 139 | 135 | 105 | 108 | 245 |
| 2661 | 2,361 | 266 | 430 | 261 | 174 | 385 |
| Median | 1,799 | 172 | 147 | 113 | 130 | 285 |
| Late | ||||||
| 1408 | 1,747 | 153 | 144 | 95 | 64 | 291 |
| 3632 | 766 | 126 | 106 | 74 | 71 | 203 |
| 1756 | 1,107 | 165 | 93 | 77 | 52 | 244 |
| 2274 | 904 | 99 | 135 | 120 | 133 | 221 |
| 2208 | 557 | 89 | 128 | 97 | 98 | 238 |
| Median | 904 | 126 | 128 | 95 | 71 | 238 |
FIG 1Proportion of defective and intact viral DNA sequences isolated from each ART treatment group. (A) Sequence classification pipeline. Sequences were classified by a process of elimination that identified the major defects within each sequence. (B) Characteristics of sequences are colored the same as those for panel A. Number of participants is noted under each group.
Number of cells and sequences obtained for each subset and participant
| Group and SCOPE PID | No. of sequences and CD4+ T-cells used for analysis | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NV | SCM | CM | TM | EM | TD | |||||||||||||
| Cells analyzed | Defective | Intact | Cells analyzed | Defective | Intact | Cells analyzed | Defective | Intact | Cells analyzed | Defective | Intact | Cells analyzed | Defective | Intact | Cells analyzed | Defective | Intact | |
| Early | ||||||||||||||||||
| 2647 | 2,008,627 | 20 | 1 | 104,356 | 2 | 0 | 606,738 | 49 | 2 | 488,060 | 35 | 0 | 557,995 | 46 | 2 | 355,176 | 38 | 1 |
| 2531 | 846,802 | 2 | 1 | 505,614 | 11 | 1 | 845,044 | 26 | 0 | 369,349 | 33 | 1 | 241,380 | 37 | 0 | 589,001 | 33 | 2 |
| 2664 | 2,460,392 | 12 | 0 | NA | NA | NA | 1,124,804 | 42 | 0 | 750,758 | 24 | 1 | 285,373 | 56 | 0 | 350,372 | 39 | 0 |
| 2606 | 2,377,831 | NA | NA | NA | NA | NA | 3,074,632 | 10 | 0 | 2,709,673 | 34 | 1 | 1,419,446 | 21 | 0 | 794,481 | 2 | 0 |
| 2454 | 944,567 | 7 | 0 | NA | NA | NA | 822,853 | 34 | 0 | 606,953 | 42 | 1 | 370,087 | 26 | 0 | NA | NA | NA |
| 2661 | 1,312,753 | NA | NA | NA | NA | NA | 1,005,587 | 1 | 0 | 978,764 | 0 | 1 | 1,125,278 | 9 | 21 | NA | NA | NA |
| Late | ||||||||||||||||||
| 1408 | 2,008,675 | 1 | 0 | NA | NA | NA | 666,109 | 39 | 0 | 288,519 | 46 | 0 | 196,068 | 20 | 6 | 231,663 | 8 | 0 |
| 3632 | 1,972,938 | 6 | 2 | 155,591 | 3 | 0 | 844,189 | 14 | 0 | 1,200,376 | 31 | 2 | 409,945 | 35 | 0 | 677,269 | 3 | 0 |
| 1756 | 2,860,172 | NA | NA | 131,518 | 2 | 0 | 1,024,396 | 15 | 0 | 997,705 | 19 | 15 | 679,114 | 18 | 22 | 175,675 | NA | NA |
| 2274 | 342,384 | NA | NA | NA | NA | NA | 1,107,273 | 25 | 1 | 825,005 | 43 | 0 | 350,637 | 25 | 10 | NA | NA | NA |
| 2208 | 1,010,249 | 36 | 0 | NA | NA | NA | 367,777 | 35 | 1 | 419,586 | 31 | 2 | 267,978 | 34 | 0 | 248,955 | NA | NA |
FIG 2Infection frequency versus cellular half-life. (A) Mixed-effects modeling of total infection frequency per 106 cells versus cellular half-life (days) for all participants and early and late ART treatment groups. (B) Mixed-effects modeling of intact infection frequency per 106 cells versus cellular half-life (days) for all participants. The black line depicts simple regression analysis. P values and R2 values can be found for all participants and each ART treatment group. Two R2 values are calculated for this model, mR2 (marginal) and cR2 (conditional), which are similar to a linear regression comparing the relationship between half-life and infection frequency for individual participants or the population as a whole. Marginal R2 is calculated using all the data points on the graph regardless of participant, whereas the conditional R2 accounts for participant variability. The slopes and 95% CIs are reported for the population-wide trend.
FIG 3Expansions of identical sequences for each ART treatment group. (A) Proportion of all sequences, either defective (blue) or intact (green), in an EIS in each CD4+ T-cell subset for all participants and early and late ART treatment groups. Data represented as means ± 95% CI. (B) The proportion of intact (green) and defective (blue) sequences that are also part of an EIS. The number of clusters that contribute to the pool of identical sequences is noted above the bars.
FIG 4Infection frequency for each cell subset in each ART treatment group. (A) Total infection frequency per 106 cells for each CD4+ T-cell subset for all participants (n = 11) and each ART treatment group, early (n = 6) and late (n = 5). (B) Intact infection frequency per 106 cells for each CD4+ T-cell subset for all participants (n = 11) and each ART treatment group, early (n = 6) and late (n = 5). Data represented as mean ± 95% CI.